Predicta Med, a Ramat Gan, Israel-based autoimmune disease detection and intervention recommendation company, received an investment from CerraCap Ventures.
The amount of the deal was not disclosed.
The company intends to use the funds to accelerate growth and expand operations and its business reach.
Led by Shlomit Steinberg-Koch, CEO, Predicta Med is an AI-based digital health company working in the field of predictive analytics to enable early detection and effective treatment selection of autoimmune and immune-related diseases. Their PredictAI™ platform aggregates, analyses, and enriches data-driven decision-making that helps healthcare providers reduce immune-related disease diagnosis from years and months to weeks. The current product suite is focused on seven immune-related diseases – Celiac, Crohn’s Disease, Ulcerative Colitis, Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus and Psoriatic Arthritis.
The company has established partnerships with healthcare providers like Hea3rt (Stanford Medicine’s Healthcare AI Applied Research Team), Hoag Memorial Hospital, Presbyterian and KSM (Kahn-Sagol-Maccabi) Research and Innovation. In addition, Predicta Med has completed Mayo Clinic Platform Accelerate, a 20-week program focused on model validation and clinical readiness designed to help early-stage health tech AI startups become market-ready.
FinSMEs
13/02/2023